These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 21312011)

  • 1. A patient presenting nasal septum perforation during bevacizumab-containing chemotherapy for advanced breast cancer.
    Petrelli F; Cabiddu M; Barbara C; Barni S
    Breast Cancer; 2011 Jul; 18(3):226-30. PubMed ID: 21312011
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Nasal septum perforation and bevacizumab].
    Bengrine-Lefevre L; Afchain P; Chibaudel B; Gervais H; Tournigand C; De Gramont A; Louvet C
    Rev Med Interne; 2011 Apr; 32(4):e43-5. PubMed ID: 21470582
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nasal septum perforation in a bevacizumab-treated patient with metastatic breast cancer.
    Traina TA; Norton L; Drucker K; Singh B
    Oncologist; 2006; 11(10):1070-1. PubMed ID: 17110625
    [No Abstract]   [Full Text] [Related]  

  • 4. Nasal septum perforation in a breast cancer patient treated with bevacizumab.
    Marín AP; Sánchez AR; Arranz EE
    Ann Oncol; 2009 Nov; 20(11):1901-2. PubMed ID: 19752003
    [No Abstract]   [Full Text] [Related]  

  • 5. Nasal septum perforation: a side effect of bevacizumab chemotherapy in breast cancer patients.
    Mailliez A; Baldini C; Van JT; Servent V; Mallet Y; Bonneterre J
    Br J Cancer; 2010 Sep; 103(6):772-5. PubMed ID: 20736943
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Perforation of the nasal septum: a rare complication of bevacizumab].
    Bylicki O; Boursier C; Peloni JM; Dot JM
    Rev Mal Respir; 2012 Nov; 29(9):1124-6. PubMed ID: 23200586
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Spontaneous nasal perforation in a bevacizumab-treated patient with metastatic breast cancer.
    Rodriguez CA; Martin T; Lozano R; Gomez A; Cruz JJ
    Breast J; 2017 Nov; 23(6):745-746. PubMed ID: 28845572
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nasal septum perforation and bevacizumab.
    Power DG; Kemeny NE
    Med Oncol; 2011 Mar; 28(1):89-93. PubMed ID: 20213219
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bevacizumab-induced nasal septum perforation.
    Fakih MG; Lombardo JC
    Oncologist; 2006 Jan; 11(1):85-6. PubMed ID: 16401718
    [No Abstract]   [Full Text] [Related]  

  • 10. A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer.
    Clegg A; Scott DA; Sidhu M; Hewitson P; Waugh N
    Health Technol Assess; 2001; 5(32):1-195. PubMed ID: 12065068
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety of intranasal Bevacizumab (Avastin) treatment in patients with hereditary hemorrhagic telangiectasia-associated epistaxis.
    Chen S; Karnezis T; Davidson TM
    Laryngoscope; 2011 Mar; 121(3):644-6. PubMed ID: 21344447
    [TBL] [Abstract][Full Text] [Related]  

  • 12. VEGF as a marker for outcome among advanced breast cancer patients receiving anti-VEGF therapy with bevacizumab and vinorelbine chemotherapy.
    Burstein HJ; Chen YH; Parker LM; Savoie J; Younger J; Kuter I; Ryan PD; Garber JE; Chen H; Campos SM; Shulman LN; Harris LN; Gelman R; Winer EP
    Clin Cancer Res; 2008 Dec; 14(23):7871-7. PubMed ID: 19047116
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Spontaneous nasal septal perforation with antiangiogenic bevacizumab therapy.
    Burkart CM; Grisel JJ; Hom DB
    Laryngoscope; 2008 Sep; 118(9):1539-41. PubMed ID: 18622319
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prospective randomized study of four novel chemotherapy regimens in patients with advanced nonsmall cell lung carcinoma: a minnie pearl cancer research network trial.
    Greco FA; Gray JR; Thompson DS; Burris HA; Erland JB; Barton JH; Litchy S; Houston GA; Butts JA; Webb C; Scott C; Hainsworth JD
    Cancer; 2002 Sep; 95(6):1279-85. PubMed ID: 12216096
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An observational study of nasal cavity toxicity in cancer patients treated with bevacizumab.
    D'Amico M; Pagano M; Pasa A; Puntoni M; Clavarezza M; Gennari A; Gozza A; Zanardi S; Defferrari C; Provinciali N; Campazzi E; Campora S; Paleari L; Marra D; Petrera M; DeCensi A
    Expert Opin Drug Saf; 2014 Nov; 13(11):1437-42. PubMed ID: 25224760
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An out-patient second-line chemotherapy with gemcitabine and vinorelbine in patients with non-small cell lung cancer previously treated with cisplatin-based chemotherapy. A phase II study of the Hellenic co-operative Oncology Group.
    Pectasides D; Kalofonos HP; Samantas E; Nicolaides C; Papacostas P; Onyenadum A; Visvikis A; Skarlos D; Fountzilas G
    Anticancer Res; 2001; 21(4B):3005-10. PubMed ID: 11712802
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A case of nasal septal perforation caused by bevacizumab for advanced cervical cancer.
    Taira Y; Shimoji Y; Nakasone T; Arakaki Y; Nakamoto T; Kudaka W; Aoki Y
    J Obstet Gynaecol Res; 2021 Feb; 47(2):833-837. PubMed ID: 33300217
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II study of gemcitabine in combination with vinorelbine versus gemcitabine followed by vinorelbine for metastatic breast cancer.
    Park IH; Ro J; Lee KS; Kim SN; Yun YH; Nam BH
    Invest New Drugs; 2010 Oct; 28(5):659-69. PubMed ID: 19575146
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Docetaxel, gemcitabine and bevacizumab as salvage chemotherapy for HER-2-negative metastatic breast cancer.
    Kontopodis E; Kentepozidis N; Christophyllakis Ch; Boukovinas I; Kalykaki A; Kalbakis K; Vamvakas L; Agelaki S; Kotsakis A; Vardakis N; Georgoulias V; Mavroudis D
    Cancer Chemother Pharmacol; 2015 Jan; 75(1):153-60. PubMed ID: 25398698
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of advanced breast cancer with gemcitabine and vinorelbine.
    Hortobagyi GN
    Oncology (Williston Park); 2001 Feb; 15(2 Suppl 3):15-7. PubMed ID: 11252883
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.